Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLoans - NetMinority InterestNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Creative Medical Technology Holdings (CELZ) Common Equity (2016 - 2025)

Creative Medical Technology Holdings (CELZ) has disclosed Common Equity for 16 consecutive years, with $5.6 million as the latest value for Q3 2025.

  • On a quarterly basis, Common Equity fell 14.72% to $5.6 million in Q3 2025 year-over-year; TTM through Sep 2025 was $5.6 million, a 14.72% decrease, with the full-year FY2024 number at $6.3 million, down 38.69% from a year prior.
  • Common Equity was $5.6 million for Q3 2025 at Creative Medical Technology Holdings, down from $6.8 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $23.0 million in Q2 2022 to a low of -$2.4 million in Q1 2021.
  • A 5-year average of $9.4 million and a median of $9.2 million in 2024 define the central range for Common Equity.
  • Peak YoY movement for Common Equity: surged 6174.45% in 2022, then crashed 45.78% in 2024.
  • Creative Medical Technology Holdings' Common Equity stood at $10.2 million in 2021, then skyrocketed by 55.27% to $15.9 million in 2022, then tumbled by 34.8% to $10.3 million in 2023, then plummeted by 38.69% to $6.3 million in 2024, then decreased by 11.82% to $5.6 million in 2025.
  • Per Business Quant, the three most recent readings for CELZ's Common Equity are $5.6 million (Q3 2025), $6.8 million (Q2 2025), and $8.1 million (Q1 2025).